Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
361 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (9)

Medical Condition

  • Show all (63)
  • Autoimmune Disorders (1)
  • Cancer (61)
    • Breast Cancer (1)
    • Head and Neck Cancer (4)
    • (-) Skin Cancer (5)
      • Squamous Cell Carcinoma (4)
    • (-) Solid Tumors (4)
  • Pediatrics (1)
Displaying 1 - 9 of 9

A study for patients with recurrent or metastatic squamous cell carcinoma of the Head and Neck using study drug MEDI4736

Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for adult subjects with head and neck cancer (oral cavity, oropharynx middle part of the throat, hypopharynx bottom part of the throat, or larynx part of throat between the base of the tongue and the windpipe) that has either returned after treatment (recurrent) or is newly…
Read More

A study for patients with advanced skin cancer of the head and neck, lung or esophagus using study drug Selinexor (KPT-330)

Condition: Cancer / Skin Cancer
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to examine the effects of KPT-330 on patients with an advanced form of skin cancer called Squamous Cell Cancer (SCC) of the head and neck, lung, or esophagus. The study drug KPT-330 is an investigational drug that
Read More

A study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck using study drug MEDI4736

Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to determine the effectiveness and safety of study drug MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 and tremelimumab combination therapy in the treatment of patients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck…
Read More

A study for patients with recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) using study drug MEDI4736

Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for patients with recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). This study will test the safety of an experimental anti-cancer drug (MEDI4736). MEDI4736 is an antibody (a protein produced by the defense system of the body immune system) that has been…
Read More

Study for patients with melanoma, non-small cell lung cancer (NSCLC) or squamous cell cancer of the head and neck (SCCHN) using drug B7-H3

Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with melanoma, non-small cell lung cancer (NSCLC), or squamous cell cancer of the head and neck (SCCHN) that has a protein called B7-H3 on the tumor cells or blood vessels in thetumor. The purpose of this study is to test the safety, tolerability, and most effective…
Read More

A study for patients with advanced solid tumors using study drug MEDI1873

Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
This study is for subjects with either cancer of the head and neck, lung cancer or colorectal cancer. The aim of this research study is to identify the best dose of an experimental drug called MEDI1873 and to see if it is safe and tolerable in subjects with advanced solid tumor types. The study…
Read More

Study of Experimental Drug GSK3359609 in Patients with Advanced Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
GSK3359609 is a drug that is a type of antibody. It is a kind of immunotherapy that targets the ICOS (anti-Inducible T cell Co-Stimulator) protein present on specific immune cells. ICOS is a cell receptor that enhances the immune response to foreign bodies, and which is expected to help your immune system find and fight cancer cells. It will also be called…
Read More

Study of TSR-042 (anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Read More

A study for patients with advanced and/or refractory solid tumors using oral drug CB-839

Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with the following types of cancer: Triple negative breast cancer, non-small cell lung cancer, mesothelioma, renal cell carcinoma, melanoma, head and and neck squamous cell carcinoma, colorectal cancer, sarcoma and pancreatic cancer. The purpose of this study is to…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science